Clarity Pharmaceuticals (ASX:CU6) Expands Radiopharmaceutical Pipeline
Clarity Pharmaceuticals (ASX:CU6) unveils a novel radiopharmaceutical, SAR-bisFAP, enhancing cancer diagnosis and treatment potential.
Clarity Pharmaceuticals (ASX:CU6) unveils a novel radiopharmaceutical, SAR-bisFAP, enhancing cancer diagnosis and treatment potential.
Perpetual Resources Ltd (ASX: PEC) reports final assays from Isabella showing ultra high-grade spodumene up to 6.8% Li2O.
Green Technology Metals (ASX:GT1) reports high-grade lithium discoveries at the Junior Lithium Project in Ontario, confirming significant potential.
Skin Elements Limited (ASX:SKN) has requested a trading halt pending significant announcements regarding a court application and capital raising.
Rhythm Biosciences (ASX:RHY) reports key milestones achieved, including the launch of ColoSTAT® Beta release candidate kits and significant financial updates.
Acrux Limited (ASX:ACR) announces a successful FDA product approval and launches a Share Purchase Plan.
Race Oncology Ltd announces a $5.25 million R&D tax refund to advance clinical development efforts for RC220.
Vection Technologies Ltd (ASX:VR1) announces the launch of full-scale Algho AI trials at Massachusetts General Hospital, showcasing significant growth potential.
dorsaVi Ltd partners with Secret Network to integrate blockchain technology, enhancing privacy and security for wearable movement data.
NOVONIX Limited announces a conditional commitment for a US$754 million loan to support its new graphite manufacturing facility in Tennessee.